Navigation Links
Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
Date:10/16/2007

multi-site phase 2 trial of XL784 was designed to enroll approximately 130 diabetic patients who have clinically significant proteinuria. Participants were randomly assigned to receive 200mg of XL784 or placebo daily for three months. The primary endpoint of the trial was a significant reduction in proteinuria compared with placebo. Secondary endpoints included changes in renal function and cardiovascular events.

About XL784

XL784 was the first small molecule compound developed by Exelixis, using its proprietary drug discovery engine. The compound is a potent inhibitor of the ADAM-10 and MMP-2 metalloprotease enzymes, targets of significant interest because of their important role in renal fibrosis and impairment. XL784 was specifically optimized to be matrix metalloprotease-1 (MMP-1) sparing, thus potentially significantly enhancing its safety profile and enabling higher dosing compared with other previously studied metalloprotease inhibitors. Results of single and repeat dose phase 1 clinical trials of XL784 administered orally to 70 healthy volunteers demonstrated that XL784 has attractive safety and pharmacokinetic profiles.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GSK, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: HTWR ... support technologies that are revolutionizing the treatment of advanced ... the fourth quarter of 2013 will be approximately $53 ... million. "Our full-year revenue growth of 87% ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... Calif., Oct 21 MAP Pharmaceuticals, Inc. (Nasdaq: ... of Thomas P. McCracken as Vice President, Intellectual ... property program in support of the potential commercialization ... inhaled migraine therapy, and other product opportunities. ...
... (San Francisco, CA and Ottawa, Ontario), a clinical-stage cancer ... Backer, Ph.D., to the newly-created position of senior vice ... all aspects of chemistry, manufacturing and controls (CMC) in ... pipeline products. "We are extremely pleased to ...
Cached Medicine Technology:MAP Pharmaceuticals Appoints Thomas P. McCracken as Vice President, Intellectual Property 2MAP Pharmaceuticals Appoints Thomas P. McCracken as Vice President, Intellectual Property 3Jennerex Names Dr. Mark P. Backer as Senior Vice President of Technical Operations 2
(Date:4/23/2014)... a researcher from the Cancer Science Institute of Singapore ... identified the cancer specific stem cell which causes gastric ... new drugs for the treatment of this disease and ... by Dr Chan Shing Leng, Research Assistant Professor at ... cancer-specific variant of a cell surface protein, CD44v8-10, marks ...
(Date:4/23/2014)... Physical Activity on Mobility Limitation in Old Age , ... of mobility limitation in old age, whereas leisure-time physical ... study which followed up 5,200 public sector employees for ... Research Center in Finland and the Finnish Institute of ... wears the body and lasts for several hours a ...
(Date:4/23/2014)... may prevent the depletion of self-control, according to research ... the Association for Psychological Science. , Self-control can be ... focus attention on a boring textbook are hard things ... this difficulty: Exerting self-control for a long period seems ... subsequent tasks. , "It is as if self-control is ...
(Date:4/23/2014)... Getting to the bottom of Alzheimer,s disease has ... turns and controversies. In the latest crook in ... insight into the interaction between proteins associated with ... journal ACS Chemical Neuroscience , could have ... K. Surewicz, Krzysztof Nieznanski and colleagues explain that ...
(Date:4/22/2014)... visited the New Jersey Institute of Technology (NJIT) ... for the launch of the New Jersey Innovation ... new model for business innovation through the leveraging ... investment. U.S. Senator Cory Booker, Panasonic Corp. of ... Jersey Lieutenant Governor Kim Guadagno, New Jersey Secretary ...
Breaking Medicine News(10 mins):Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:ADHD drug may help preserve our self-control resources 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2
... Instead of dismissing grumblings about being tired or exhausted, ... to a worsened health state or even death, says ... ,Dr. Karin Olson, a U of A professor from ... between tiredness, fatigue and exhaustion and that recognizing those ...
... study has found that a brief session of muscle-building exercise ... response.// ,The immune system’s reaction differs markedly between ... process remains unclear. ,“We’re trying to find ... benefit your vaccine response,” said lead author Kate Edwards, Ph.D., ...
... in the United States over age 20 are affected ... from the Johns Hopkins Bloomberg School of Public Health. ... age, cardiovascular disease, diabetes and a lack of physical ... lifestyle changes, such as increased physical activity and measures ...
... is a condition resulting from inflammation of joints. ... movement.// ,Spondylarthritis (SpA), ankylosing spondylitis (AS), ... all associated rheumatic diseases collectively known as "spondyloarthropathies".,Aside ... by ankylosis, stiffness and fusion of bone in ...
... which the bone mass in the body becomes reduced// and ... normally affects postmenopausal women. ,A McMaster University researcher ... a woman's problem but that the bone-wasting disease can severely ... professor of clinical medicine, and a group of five Canadian ...
... brain cell came from remain distinct even after the cell ... will report in the February 1 issue of Cancer Research. ... complexity to the quest to understand the causes of childhood ... Ph.D., the Donald O. Schnuck Family Professor of Neurology at ...
Cached Medicine News:Health News:Take Fatigue Seriously - Says Researcher 2Health News:Take Fatigue Seriously - Says Researcher 3Health News:Muscle-Building Exercise Improves Response to Flu Shot 2Health News:More Than 18 Million US Men Affected by ED 2Health News:Does Anti-TNF Therapy Control Ankylosis ? 2Health News:Osteoporosis Does Not Spare Men Either 2Health News:Genetic Fingerprints Identify Brain Tumors' Origins 2
... Vibratome Semi-Automatic Tissue Sectioning System has maintained ... sectioning system. Researchers from around the globe ... for their fresh and fresh fixed tissue ... With the Vibratome Automatic Tissue Sectioning ...
... 1500 Sectioning System provides a versatile means ... plant tissues. The 1500 employs a ... freezing or embedding. The creation of ... of enzyme activities, and other deleterious effect ...
... Semi-Automatic Tissue Sectioning System has maintained the ... system. Researchers from around the globe have ... their fresh and fresh fixed tissue sectioning ... With the Vibratome Automatic Tissue Sectioning Systems, ...
... The NEW Vibratome 3000 Plus Sectioning ... fresh or fixed, animal, or plant tissues. ... principle which allows sectioning without freezing or ... alteration of morphology, the destruction of enzyme ...
Medicine Products: